Imatinib Mesylate, Interferon Alfa, and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Imatinib Mesylate, Interferon Alfa, and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

This study is currently recruiting participants.

Study NCT00363649. Last updated on October 22, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00363649

Locations


United States, Maryland
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Recruiting
	Baltimore, Maryland, United States, 21231
	Contact: B. Douglas Smith, MD 410-614-5068 smithdo@jhmi.edu

Sponsors and Collaborators

Sidney Kimmel Comprehensive Cancer Center

National Cancer Institute (NCI)

Investigators


Principal Investigator:	B. Douglas Smith, MD	Sidney Kimmel Comprehensive Cancer Center